Cytomegalovirus-vectored COVID-19 Vaccines Elicit Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.2) in Mice

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2023 Nov 16

PMID 37971259

Authors

Jian Liu

Dabbu Kumar Jaijyan

Yanling Chen

Changcan Feng

Shaomin Yang

Zhenglong Xu

Nichun Zhan

Congming Hong

Shuxuan Li

Tong Cheng

Hua Zhu

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus (CMV) has been used as a novel viral vector for vaccine development and gene therapy. Coronavirus disease 2019 is an infectious disease caused by the SARS-CoV-2 virus, which is highly mutable and is still circulating globally. The study showed that the CMV viral vector caused transient systemic infection and induced robust transgene expression . CMV vectors expressing different SARS-CoV-2 proteins were immunogenic and could elicit neutralizing antibodies against a highly mutated Omicron variant (BA.2). The expression level of receptor-binding domain (RBD) protein was higher than that of full-length S protein using CMV as a vaccine vector, and CMV vector expression RBD protein elicited higher RBD-binding and neutralizing antibodies. Moreover, the study showed that CMV-vectored vaccines would not cause unexpected viral transmission, and pre-existing immunity might impair the immunogenicity of subsequent CMV-vectored vaccines. These works provide meaningful insights for the development of a CMV-based vector vaccine platform and the prevention and control strategies for SARS-CoV-2 infection.

Citing Articles

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies.

Banda A, Impomeni O, Singh A, Baloch A, Hu W, Jaijyan D Vaccines (Basel). 2024; 12(6).

PMID: 38932365 PMC: 11209408. DOI: 10.3390/vaccines12060636.

References

Adler H, Messerle M, Wagner M, Koszinowski U . Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol. 2000; 74(15):6964-74. PMC: 112213. DOI: 10.1128/jvi.74.15.6964-6974.2000. View

Cosar B, Karagulleoglu Z, Unal S, Ince A, Uncuoglu D, Tuncer G . SARS-CoV-2 Mutations and their Viral Variants. Cytokine Growth Factor Rev. 2021; 63:10-22. PMC: 8252702. DOI: 10.1016/j.cytogfr.2021.06.001. View

Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020; 11(1):4207. PMC: 7442803. DOI: 10.1038/s41467-020-18077-5. View

Tsuda Y, Caposio P, Parkins C, Botto S, Messaoudi I, Cicin-Sain L . A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis. 2011; 5(8):e1275. PMC: 3153429. DOI: 10.1371/journal.pntd.0001275. View

Boppana S, Rivera L, Fowler K, Mach M, Britt W . Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001; 344(18):1366-71. DOI: 10.1056/NEJM200105033441804. View

Klenerman P, Oxenius A . T cell responses to cytomegalovirus. Nat Rev Immunol. 2016; 16(6):367-77. DOI: 10.1038/nri.2016.38. View

Costa Verdera H, Kuranda K, Mingozzi F . AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol Ther. 2020; 28(3):723-746. PMC: 7054726. DOI: 10.1016/j.ymthe.2019.12.010. View

Cromer D, Steain M, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2021; 3(1):e52-e61. PMC: 8592563. DOI: 10.1016/S2666-5247(21)00267-6. View

Lusvarghi S, Wang W, Herrup R, Neerukonda S, Vassell R, Bentley L . Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J Virol. 2021; 96(1):e0111021. PMC: 8754225. DOI: 10.1128/JVI.01110-21. View

10.

Adler S, Lewis N, Conlon A, Christiansen M, Al-Ibrahim M, Rupp R . Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. J Infect Dis. 2019; 220(3):411-419. DOI: 10.1093/infdis/jiz141. View

11.

Wang R, Chen J, Gao K, Wei G . Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics. 2021; 113(4):2158-2170. PMC: 8123493. DOI: 10.1016/j.ygeno.2021.05.006. View

12.

Adler S, Hempfling S, Starr S, Plotkin S, Riddell S . Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J. 1998; 17(3):200-6. DOI: 10.1097/00006454-199803000-00006. View

13.

Hasenkrug K, Feldmann F, Myers L, Santiago M, Guo K, Barrett B . Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques. mBio. 2021; 12(4):e0150321. PMC: 8406331. DOI: 10.1128/mBio.01503-21. View

14.

Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J . The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2022; 613(7942):130-137. DOI: 10.1038/s41586-022-05522-2. View

15.

Liu J, Jaijyan D, Tang Q, Zhu H . Promising Cytomegalovirus-Based Vaccine Vector Induces Robust CD8 T-Cell Response. Int J Mol Sci. 2019; 20(18). PMC: 6770317. DOI: 10.3390/ijms20184457. View

16.

Selariu A, Cheng T, Tang Q, Silver B, Yang L, Liu C . ORF7 of varicella-zoster virus is a neurotropic factor. J Virol. 2012; 86(16):8614-24. PMC: 3421744. DOI: 10.1128/JVI.00128-12. View

17.

Priddy F, Brown D, Kublin J, Monahan K, Wright D, Lalezari J . Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46(11):1769-81. DOI: 10.1086/587993. View

18.

Farrell H, Oliveira M, MacDonald K, Yunis J, Mach M, Bruce K . Luciferase-tagged wild-type and tropism-deficient mouse cytomegaloviruses reveal early dynamics of host colonization following peripheral challenge. J Gen Virol. 2016; 97(12):3379-3391. PMC: 6542255. DOI: 10.1099/jgv.0.000642. View

19.

Lai Y, Yue Y, Duan D . Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther. 2009; 18(1):75-9. PMC: 2839223. DOI: 10.1038/mt.2009.256. View

20.

Hansen S, Zak D, Xu G, Ford J, Marshall E, Malouli D . Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nat Med. 2018; 24(2):130-143. PMC: 5909823. DOI: 10.1038/nm.4473. View